Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes

Bispebjerg University Hospital0 个研究点目标入组 26 人开始时间: 2017年2月7日最近更新: 2020年12月7日

试验速览

暂无简介。

•Type 2 diabetes mellitus defined as medical treatment with antidiabetic drugs for 12 weeks prior to randomization
•40-80 years of age
•eGFR=45 l per minute per 1.73 m2 of body surface area
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 13
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 13

•Allergy to Empagliflozin or its components
•Hba1c<58 mmol/mol
•Previous myocardial infarction involving the LAD supply area
•Previous coronary artery by-pass graft (CABG) operation
•Reversible myocardial ischemia assessed by adenosine stress echocardiography
•Indication of moderate-severe liver disease
•Pre-menopausal women (last menstruation =1 year prior to informed consent) who are nursing, pregnant, or of child-bearing potential and are not practicing an acceptable method of birth control throughout the study.
•Pregnancy (pregnancy test will be done at inclusion)
•Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake
•Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial or participating in another trial involving an investigational drug.

发起方

Bispebjerg University Hospital